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ABSTRACT
The aim of this study was to assess 
pathogen DNA extraction with a new 
spin column-based method (DNA-XT). 
DNA from either whole-blood samples 
spiked with Plasmodium falciparum 
or Leishmania donovani amastigote 
culture was extracted with DNA-XT 
and compared with that produced by a 
commercial extraction kit (DNeasy®). 
Eluates from large and small sample 
volumes were assessed by PCR and 
spectroscopy. Using a small volume 
(5 μl) of blood, the DNA-XT and DNeasy 
methods produced eluates with similar 
DNA concentrations (0.63 vs 1.06 ng/
μl, respectively). The DNA-XT method 
produced DNA with lower PCR inhibition 
than DNeasy. The new technique was 
also twice as fast and required fewer 
plastics and manipulations but had 
reduced total recovered DNA compared 
with DNeasy.
METHOD SUMMARY
DNA-XT, which is designed for small 
sample volumes, uses a 5-min detergent 
and enzymatic lysis step to release DNA 
from cells. Contaminating proteins and 
lipids are then bound to a matrix within 
a spin column during a 1-min centrifu-
gation step while DNA passes directly 
through.
DNA extraction is an essential starting point 
for methodologies such as PCR, which is 
used in the laboratory for molecular biology 
and clinical diagnostics. It was first achieved 
in 1869 by Friedrich Meischer [1], but a 
routine laboratory procedure was not 
developed until 1958 [2]. Today, a variety of 
methodologies are available (reviewed by 
Griffiths and Chacon-Cortes [3]); however, 
commercial spin column purification of DNA 
from blood and other tissues and fluids is 
the most common approach used in modern 
laboratories. The technique, which origi-
nated in 1979 [4], uses silica matrices to 
selectively bind DNA, allowing washing 
before elution of the purified product.
NanoMal was an EU-funded industrial–
academic consortium that was brought 
together with the aim of developing a simple-
to-use, affordable, handheld diagnostic 
device to detect malaria infection and the 
drug resistance status of the parasite by 
identifying associated genetic mutations. 
The cartridge-based assay was designed 
to use only a finger prick of blood, with 
results being obtained approximately 20 min 
after sampling. The diagnostics platform 
technology developed by our industrial 
partner, QuantuMDx Group Ltd (Newcastle 
upon Tyne, UK), incorporates a novel DNA 
extraction technique that allows DNA from 
lysed whole blood (or other sample types) to 
flow straight through a proprietary material, 
but cellular debris is retained. The resulting 
eluate contains DNA that is of a quality that 
can be used directly in PCR; therefore, the 
technique removes the need for additional 
washing and elution steps, which greatly 
simplifies the extraction procedure. During 
the NanoMal project, QuantuMDx created 
a standalone, spin column-based version 
of this easy-to-use extraction method-
ology called DNA-XT, which is optimized for 
human whole blood. Small-volume samples 
are lysed and placed over a column of the 
proprietary material, which is housed within 
a microcentrifuge collection tube. Following 
centrifugation, the resulting eluate contains 
purified, high-quality gDNA.
Here, we examine the performance 
characteristics of DNA-XT in parallel with 
a widely used commercial DNA extraction 
spin column kit for the isolation of parasite 
DNA from small volumes of Plasmodium 
falciparum-infected erythrocytes spiked 
into human whole blood (as a model for 
blood infections) and purified Leishmania 
donovani amastigotes (as might be required 
in a laboratory setting). The two primary 
objectives were to determine the efficiency 
of gDNA extraction and the quality of the 
isolated gDNA by undertaking parasite-
specific PCR. Secondary objectives were 
to assess the level of operator input, the 
time required for extractions and the use 
of reagents or consumables.
MATERIALS & METHODS
Parasites
P. falciparum 3D7 parasites were cultured in 
human red blood cell (RBC) suspensions 
using RPMI 1640 medium (Sigma-Aldrich, 
MO, USA; cat. no. R0883-500ML) supple-
mented with 2-mM l-glutamine, 35-mM 
HEPES, 0.5% (w/v) AlbuMAX™ I (Thermo 
Fisher Scientific, MA, USA), 0.2-mM 
hypoxanthine and 50-μg/ml gentamycin, 
and were maintained at 37°C under 5% CO2. 
Parasite growth was followed by micro-
scopic examination of Giemsa-stained thin 
blood smears and maintained at ≤10% 
parasitemia, with an approximately 2% 
hematocrit. Synchronization of early tropho-
zoite stages was achieved by incubating 
infected RBCs (iRBCs) in 5% (w/v) sorbitol 
for 10–20 min at room temperature [5]. L. 
donovani amastigotes were harvested from 
the spleens of donor mice. Briefly, female 
RAG1B6 KO mice, infected with L. donovani 
at least 60 days before, were humanely 
killed. At necropsy, spleens were dissected 
and homogenized, and the amastigotes 
harvested by differential centrifugation [6].
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Sample preparation
For fresh whole blood spiked with P. falci-
parum iRBCs, stock iRBCs with 8–10% 
parasitemia were diluted in fresh whole 
blood (Cambridge Biosciences, Cambridge, 
UK) to attain a parasitemia of 1%. Two 
additional tenfold dilutions were performed 
to obtain samples with parasitemias of 0.1 
and 0.01%. The parasitemias of the 1 and 
0.1% samples were confirmed by microscopy 
(Supplementary file 1). Nonspiked fresh 
whole blood was used as a negative control. 
As a reference, levels of parasitemia of 
0.1–0.2% (5000–10,000 parasites per μl of 
blood) are generally accepted to be the point 
at which fever begins and a patient becomes 
symptomatic for P. falciparum malaria [7]. 
For Leishmania parasite preparations, 
parasites (amastigotes) were washed twice 
in RPMI 1640 without serum prior to counting 
and were used at a concentration of 
1 × 107/ml.
Column purification
For iRBC-spiked fresh whole blood, the 
DNeasy® Blood & Tissue Kit (Qiagen, Hilden, 
Germany) and DNA-XT™ DNA extraction kit 
(QuantuMDx) were used to process samples. 
Samples (iRBC-spiked or nonspiked fresh 
whole  blood) were processed following the 
manufacturer’s instructions (blood 
protocols). A 10-μl sample volume was used 
for the DNA-XT kit and a 100-μl sample 
volume for the DNeasy kit (termed Q100). 
Notably, only 40 μl of the 80-μl lysis step is 
passed though DNA-XT columns after initial 
processing; thus, only 5 μl of the original 
blood sample passes through the column 
(Figure 1). In light of this, an additional arm 
of the study used DNeasy columns with a 
5-μl sample volume (termed Q5) to allow a 
more direct comparison of the two extraction 
methodologies.
For Leishmania parasite preparations, the 
same two DNA extraction kits were used to 
process samples. For the DNA-XT kit, 10 μl 
of sample was used, following the manufac-
turer’s instructions (blood protocol); for the 
DNeasy kit, 5 μl of sample was used, again 
following the manufacturer’s instructions 
(nucleated blood protocol).
DNA quantitation
The volume of the eluate (although techni-
cally flow-through in the case of the DNA-XT 
kit) was noted and the DNA concentration 
determined by fluorescence using a Qubit™ 
spectrophotometer (Thermo Fisher Scien-
tific). The two kits have a fivefold difference 
in final eluate/flow-through volume, with 
DNeasy recommending eluting in 200 μl and 
DNA-XT having a flow-through of approxi-
mately 40 μl.
PCR
PCR targeting P. falciparum β tubulin 
(PfBetaT) was performed using Phire™ Hot 
Start II DNA Polymerase (Thermo Fisher 
Scientific). Two volumes of template (1 and 
10 μl) were used in parallel reactions with 
p r i m e r s  ( P f B e t a T  F , 
5′-TTGGGGTCCTTCCCCTTTATTGTAT-3′; 
PfBetaT R, 5′-CAAAGGGGCCAGCAC-
GAACACT-3′) at final concentrations of 
200 nM. Cycling conditions were 95°C for 
30 s, then 35 cycles of 95°C for 30 s, 55°C for 
30 s and 68°C for 30 s, followed by 68°C for 
10 min.
PCR targeting L. donovani kineto-
plast DNA (high copy number) and DNA 
polymerase I (Pol I; low copy number) was 
performed using Phusion™ polymerase 
(Thermo Fisher Scientific). Volumes of 
1 and 10 μl L. donovani eluate were used, 
respectively, with primers for the kineto-
plast DNA (LdKinetoplast F2, 5′-CCAAT-
GAAGCCAAGCCAGTG-3′; LdKinetoplast 
R2, 5′-GGCTGGTTTTAGATGTGGGC-3′) 
and DNA Pol I (LdDNApol I F, 5′-TGTCGCTT-
GCAGACCAGATG-3 ′; LdDNApol I R, 
5′-GCATCGCAGGTGTGAGCAC-3′) [8] at 
final concentrations of 200 nM. Cycling 
conditions were 98°C for 30 s, then 10 
cycles of 10 s at 98°C, 10 s at 69–59°C 
touchdown and 2 s at 72°C, followed by 
20 cycles of 10 s at 98°C, 10 s at 59°C and 
2 s at 72°C, which were followed by 72°C for 
5 min. PCR products were electrophoresed 
on 1% (w/v) agarose gels and visualized 
with UV.
Statistical analysis
For the eluate DNA concentrations, a 
Student’s t-test (unpaired, equal variance) 
was performed using Prism Mac 6.0h 
(GraphPad Software, CA, USA).
RESULTS & DISCUSSION
Extraction
Process timings
The time to complete extractions from eight 
samples using each of the kits was recorded. 
For the DNA-XT kit, the extractions took 
between 50 and 60 min, compared with 
120–130 min for the DNeasy kit.
 
Prepare column
(DNA-XT™
activation
buffer)
Incubate
Pure DNA
Tube
(supplied)
(DNA-XT™
lysis buffer)
Sample
Figure 1. DNA-XT protocol. Sample preparation: 10 μl of blood/sample was added to 70 μl of lysis 
buffer, and the mixture was incubated at 55°C for 10 min. Column preparation: 350 μl of buffer was 
added prior to centrifugation (1400 ×g, 3 min), and 40 μl of incubated lysis buffer/sample was added 
to the prepared column and incubated at room temperature for 3 min prior to centrifugation (1400 
×g, 3 min).
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Manipulations
The number of manipulations required to 
perform the extractions was also tallied. For 
an individual sample, the DNA-XT kit required 
14 manipulations, whereas the DNeasy kit 
required 25. A manipulation was considered 
to be any change of tip or tube/wash column 
or any action (e.g., centrifugation or incubation 
step). In terms of plastics usage for a single 
sample, the DNA-XT kit used five tips and four 
tubes (including the column), and the DNeasy 
kit required eight tips and seven tubes.
Eluate characteristics
P. falciparum
All three column extraction arms (Q100, Q5 
and DNA-XT) had eluates that contained 
DNA, as measured by fluorescence 
spectrometry (Table 1). Given that the 
theoretical amount of human DNA in each 
sample far exceeds that of any parasite DNA, 
samples spiked with different levels of iRBCs 
were analyzed both alone and together when 
comparing yields. Unsurprisingly, in the Q100 
arm there was a greater yield of DNA than in 
the Q5 arm. This difference was 21-fold 
(mean ± SEM, 4420 ± 340 vs 205 ± 11 ng; 
n = 12), which is in line with the different 
volumes of blood processed in the Q100 and 
Q5 arms (100 and 5 μl, respectively). 
Assessing the Q5 and DNA-XT arms where 
the same amount of sample was passed 
through the respective column, similar 
concentrations of DNA were obtained (mean 
± SEM, 0.63 ± 0.04 vs 1.06 ± 0.06 ng/μl, 
respectively; n = 12), with the Q5 arm 
performing significantly better (p = 0.013), 
Table 1.  Eluate characteristics for Plasmodium falciparum-spiked whole blood-derived samples.
Column Parasitemia   Eluate volume (mean ± SEM, μl)
[DNA] (mean ± SEM, ng/
μl)
Total DNA yield 
(mean ± SEM, ng) n
Q100 Overall 197 ± 1.4 22.4 ± 1.6 4420 ± 340 12
 1%  22.1 ± 1.5 4320 ± 290 3
 0.1%  21.4 ± 2.2 4260 ± 500 3
 0.01%  24.5 ± 0.5 4880 ± 170 3
 0%  21.5 ± 1.1 4210 ± 210 3
Q5 Overall 194 ± 0.4 1.06 ± 0.06 205 ± 11 12
 1%  1.06 ± 0.02 204 ± 4.5 3
 0.1%  1.09 ± 0.12 211 ± 23 3
 0.01%  1.08 ± 0.03 209 ± 5.6 3
 0%  1.02 ± 0.05 197 ± 10 3
DNA-XT Overall 42 ± 0.4 0.63 ± 0.04 26.3 ± 1.7 12
 1%  0.65 ± 0.03 28.4 ± 1.1 3
 0.1%  0.59 ± 0.05 24.8 ± 2.3 3
 0.01%  0.68 ± 0.05 28.9 ± 2.6 3
 0%  0.55 ± 0.07 22.8 ± 3.7 3
Table 2.  Eluate characteristics for purified Leishmania donovani amastigote samples.
Column   Eluate volume (μl) [DNA] (ng/μl) Total DNA yield (ng)
Q5 Mean ± SEM 193 ± 1.2 0.06 ± 0.002 11 ± 0.4
 A 191 Too low nd
 B 195 0.06 11
 C 193 0.05 10
DNA-XT Mean ± SEM 42 ± 0.3 0.17 ± 0.01 7.3 ± 0.2
 A 42 0.16 6.6
 B 42 0.11 7.2
 C 43 0.19 8.1
nd: Not determined.
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albeit by 1.7-fold (only a single batch of each 
column type was tested here). Notably, the 
volume of eluate produced when using each 
manufacturer’s protocol is different: ∼200 μl 
for Q100 and Q5 and ∼40 μl for DNA-XT. Thus, 
the total DNA yield from the Q5 column was 
higher than that of the DNA-XT column 
(7.8-fold).
L. donovani
For the L. donovani extractions, only the Q5 
and DNA-XT protocols were used (i.e., those 
that use 5 μl of sample). Both Q5 and DNA-XT 
had eluates that contained detectable, albeit 
low, levels of DNA, with the exception of one 
replicate of the Q5 arm (Table 2). Again, 
similar concentrations of DNA were obtained 
in the Q5 and DNA-XT arms (mean ± SEM, 
0.06 ± 0.002 vs 0.17 ± 0.01 ng/μl, respectively; 
n = 2 or 3), with the DNA-XT arm performing 
slightly better by 2.8-fold. Due to the different 
eluate volumes, the total DNA yield from the 
Q5 column was slightly higher than that of 
the DNA-XT column (1.5-fold).
Parasite DNA quality
P. falciparum
While the DNA extracted in these experi-
ments reflects human DNA predominantly, 
parasite DNA was collected from spiked 
samples. Its presence and quality in eluates 
were determined by PCR detection of 
PfBetaT. Two different volumes of eluate 
were used, a low volume (1 μl) and a high 
volume (10 μl). In most cases, amplicon 
bands of the appropriate size (388 bp) could 
be detected in samples in which parasite 
DNA should be present (Figure 2). When 
using the low volume of eluate, the strongest 
bands were produced from the Q100 eluates. 
This was to be expected, as the Q100 eluates 
contain the highest total DNA concentra-
tions (Table 1). Bands were also visible, 
though fainter, in lanes using Q5 and DNA-XT 
samples, even at the lowest (0.01%) 
parasitemia used. However, when a greater 
(tenfold) volume of eluate was used, only the 
DNA-XT-derived samples resulted in positive 
amplicon bands in a parasitemia-dependent 
manner. This suggests an apparent inhibition 
of PCR when using high volumes of the Q5 
and Q100 samples. The findings presented 
in Figure 2 are supported by data from three 
independent repeats of the experiment (with 
duplicate technical repeats within each). The 
number of positive bands in each (see 
Supplementary file 2 for PCR gel images not 
present in the main text) are presented in 
Table 3. 
L. donovani
DNA was successfully amplified from 
low-volume (1 μl) eluates of purified L. 
donovani amastigotes derived from Q5 and 
DNA-XT extraction technologies when 
targeting the kinetoplast, a high copy 
number DNA sequence (Figure 3A). 
Targeting a single copy number gene, Leish-
mania spp. DNA Pol I, a PCR amplicon, was 
obtained with a larger volume (10 μl) of 
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Figure 2. Plasmodium falciparum DNA from 
spiked whole blood determined by PfBeta 
tubulin PCR. (A) Low-volume eluate template, 
1 μl. (B) High-volume eluate template, 10 μl. 
Percentage denotes the parasitemia after 
spiking.
M: 100-bp marker; NTC: No template control.
Table 3.  PCR positive outcomes for Plasmodium falciparum-spiked whole blood-derived samples.
Human whole blood 1% parasitemia (pos/total)
0.1% parasitemia (pos/
total)
0.01% parasitemia 
(pos/total) 0% unspiked (pos/total)
High-volume template Q5 2/6 2/6 2/6 0/6
High-volume template 
Q100
0/6 1/6 0/6 0/6
High-volume template 
DNA-XT
6/6 6/6 6/6 0/6
Low-volume template 
Q100
6/6 6/6 5/6 0/6
Low-volume template Q5 5/6 6/6 6/6 0/6
Low-volume template 
DNA-XT
6/6 6/6 5/6 0/6
pos: Gel band positive.
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Figure 3. Leishmania donovani DNA extracted 
from purified amastigotes and determined by 
PCR targeting the kinetoplast sequence. (A) 1 μl 
of eluate from each manufacturer’s column was 
used as a template. (B) 10 μl of eluate from each 
manufacturer’s column was used as a template. 
Eluates from three separate columns for each 
manufacturer were used.
M: 100-bp marker; NTC: No template control; 
POS: Positive control.
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DNA-XT-derived eluate, but not with 
Q5-derived eluate (Figure 3B). 
Here, a simple process for the extraction 
of DNA from small, parasite-containing 
culture samples was assessed against a 
standard commercial, spin column-based 
extraction process that is widely used in 
research and diagnostic laboratories. A 
considerable difference between the two 
techniques is that DNA is retained on the 
Qiagen DNeasy mini spin column prior to 
elution, but the QuantuMDx DNA-XT column 
retains contaminants and only the DNA is 
eluted in one centrifugation step. The advan-
tages of this process, as demonstrated 
in this study, are time savings, reduced 
plastics use, reduced reagent use (including 
removing the necessity to use guanidinium 
chloride) and a reduction in PCR-inhibiting 
contaminants. However, total yields of DNA 
are much lower, generally, when using the 
DNA-XT protocol.
The DNA-XT methodology is similar 
to a previously described DNA isolation 
method that uses a polyaniline-containing 
silica sorbent [9]. In terms of ease of use, 
the DNA-XT methodology is also compa-
rable with DNA extraction protocols that use 
Chelex® 100 (Bio-Rad Laboratories, CA, USA). 
Both of these alternative DNA extraction 
techniques have been used for forensics 
applications and perform well with samples 
that have low DNA concentrations [10-12]. 
In this study, DNA-XT was used to extract 
DNA from whole blood spiked with P. falci-
parum-infected RBCs, simulating a clinical 
diagnostic sample, and purified L. donovani 
amastigotes, as might be used in a research 
laboratory. In both cases, it was possible to 
amplify parasite DNA, although the majority 
of DNA in whole-blood extracts would be 
expected to be human DNA. Furthermore, 
with comparable input volumes, the DNA-XT 
technology compared favorably with the 
Qiagen extraction kit. Thus, DNA-XT has 
potential uses within laboratories where 
DNA extraction is required from small 
sample volumes.
The technology behind DNA-XT was 
designed for microfluidic-based, point-
of-care, molecular diagnostics platforms, 
where cell lysis and DNA extraction occur 
within a cassette to provide DNA for micro-
fluidic PCR and subsequent amplicon 
sensing. In the case of malaria diagnosis at 
point-of-care (and other diseases caused by 
blood-borne pathogens), capillary sampling 
from finger or heel pricks are the preferred 
options to generate test samples for parasite 
detection. Capillary sampling can be safely 
performed by staff with basic training and 
is often quicker and less stressful when 
compared with venepuncture [13]. Capillary 
sampling has also been used extensively 
for epidemiological studies of malaria with 
the use of blood spot collection on filter 
paper [14-16].
FUTURE PERSPECTIVE
Because DNA-XT has been demonstrated 
here to produce high-quality parasite gDNA 
(seemingly free of the types of PCR inhibitors 
that frequently contaminate whole-blood 
extracts [17-19]), this technology may also 
be useful for extracting blood from dried 
blood spots, as has been demonstrated for 
other DNA extraction methodologies [20]. 
Further applications for high-quality DNA 
extraction include genotyping for thera-
peutic diagnostics (e.g., parasite drug resis-
tance/susceptibility) and epidemiology for 
monitoring asymptomatic individuals [21,22] 
and those with submicroscopic parasitemia 
within a population [23]. These could be 
particularly useful in potential eradication 
programs [24-26]. Future work for diagnostic 
applications for the DNA-XT technology 
should include patient samples and a larger 
sample size to field-test this new technology. 
In addition, a more accurate method of DNA 
quantification should be used in these proof-
of-concept studies, namely quantitative 
PCR.
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